[Today's headlines]
Tencent (00700) mixed elements: Hy4 calls have surged, and WorkBuddy has been expanded tenfold
The Zhitong Finance App learned that on November 5, Tencent Hybrid Yuan issued an announcement stating that since H1 HY4 was first connected to WorkBuddy on November 4, 2026, it has received positive experiences and enthusiastic feedback from users and developers with significant improvements in its agent capabilities. On the first day of launch, a large number of users hit the quota in the WorkBuddy task queue.
In order to guarantee everyone's user experience, the Hy4 inference cluster has been urgently expanded tenfold and the free experience quota for users has been increased, and resources will continue to be dynamically allocated.
[General outlook]
The US stock indices all plummeted, and popular Chinese securities bucked the trend and rose
Overnight, the Dow Jones Industrial Average fell 1833.06 points, or 3.44%, to close at 51523.06 points; the S&P 500 stock index fell 334.89 points to close at 7353.73 points, or 4.36%; and the Nasdaq Composite Index fell 1421.51 points to close at 24315.0 points, or 5.52%.
Big tech stocks generally fell, with Apple down 1.53%, Amazon down 2.19%, Google-A down 2.20%, Microsoft down 3.58%, and Meta down 3.96%. The AI industry chain suffered a severe setback. The Philadelphia Semiconductor Index fell more than 12%, Nvidia, Qualcomm, and Asmack fell more than 9%, Intel fell more than 10%, and AMD fell more than 17%; the memory chip sector led the decline, with SanDisk falling 22.26%, Micron Technology falling 17.46%, Western Digital falling 17.35%, and Seagate Technology falling 16.25%. The market feared that the Democrat-led Congress would tighten data center approval restrictions to suppress storage demand and product prices.
The optical communications sector fell sharply at the same time. Applied Optoelectronics fell 20.89%, Lumentum fell 18.68%, Ciena fell 15.22%, Fabrinet fell 14.25%, Corning fell 12.92%, and major data center construction towns such as Texas and Georgia voiced opposition to expansion or delayed AI capital expenditure.
Musk's huge political investment raised concerns in the market. Tesla and SpaceX both fell, with Tesla falling 10.77% and SpaceX falling 9.05%.
Popular Chinese securities bucked the trend, and the Nasdaq China Golden Dragon Index rose 0.43%. NetEase rose 4.37%, JD rose 3.28%, Alibaba 2.64%, and Bilibili 2.67%. The Hang Seng Index ADR declined. On a proportional basis, it closed at 24368.50 points, down 428.48 points or 1.73% from the Hong Kong closing.
WTI crude oil futures on the New York Mercantile Exchange rose 2.47 US dollars in the same month to 90.59 US dollars per barrel, or 2.80%. COMEX gold futures rose by $20.40 in the same month, or 0.50%, to $4093.4 per ounce.
[Hot Topics Preview]
The US Democratic Party wants to push for a ban on super AI: 20 years in prison for individuals and forced dissolution of companies is comparable to illegal development of nuclear weapons
According to Financial News Overseas Information, on November 4, local time, US Representative Asamin Ansari (Arizona) wrote on a social networking platform: “At the top of the agenda for the first day, the Democratic Party needs to suspend the development of advanced artificial intelligence, regulate the uncontrolled industry, and ban artificial superintelligence.” This post was posted less than 24 hours after the Democratic Party took back control of both houses of the Senate and the House of Representatives in the midterm elections. Notably, Ansari's call for a “ban on artificial superintelligence” was not an impromptu proposal. The Senate version S.5493 was proposed by Bernie Sanders on September 23, and the House version H.R. 10538 was proposed by Casal on September 24. Currently, they are all “pending” and have not passed the committee's review.
Huaqin Technology (03296) plans to increase capital by 1 billion yuan to Jingyi Integrated
Huaqin Technology (03296) announced that the company's wholly-owned subsidiary plans to jointly increase capital with Jinghe Integration and Hefei Construction Investment at a price of 1.00 yuan/registered capital to Jingyi Integrated, a wholly-owned subsidiary of CRIC. The parties intend to increase the total capital by 91 billion yuan in monetary terms. Among them, the company's wholly-owned subsidiary plans to invest 1 billion yuan. Prior to this capital increase, Hefei Qinhe did not hold shares in Jingyi Integrated; after the capital increase was completed, Hefei Qinhe held 9.01% of Jingyi Integrated's shares.
Jinghe Integration (02249): It is proposed to increase Jingyi's capital by 9.1 billion yuan with Hefei Construction Investment and Hefei Qinhe
According to the Jinghe Integrated announcement, the company plans to jointly increase the capital of its wholly-owned subsidiary Jingyi Integrated with Hefei Construction Investment and Hefei Qinhe at a price of 1 yuan/registered capital, for a total capital increase of 9.1 billion yuan. Among them, the company invested 5.1 billion yuan, Hefei Construction Investment 3 billion yuan, and Hefei Qinhe invested 1 billion yuan. After the capital increase is completed, the registered capital of Jingyi Integrated will increase from 2 billion yuan to 11.1 billion yuan, and the company's shareholding ratio will be reduced from 100% to 63.96%. It is still the holding subsidiary Jingyi Integrated as the main builder of the fourth phase of the Crystal Integration project, with a total investment of 35.5 billion yuan. It is currently building a 12-inch wafer manufacturing production line with a production capacity of about 55,000 pieces/month, focusing on 40 nm and 28 nm CIS, OLED and logic processes. The products can be widely used in OLED display panels, AI phones, AI computers, smart cars and artificial intelligence.
Quanxin Bio-B (02509) and CALDERA THERAPEUTICS have signed an exclusive licensing agreement for preclinical bispecific antibody programs targeting TL1A and IL-17
Under the terms and conditions of the license agreement, Caldera Therapeutics is granted the exclusive, royalty-payable, transferable and sublicensable right to research, develop, register, manufacture and commercialize candidate products derived from the licensed project on a global scale. In return, the company or its designated subsidiary will be entitled to receive a one-time, non-refundable and non-deductible down payment of $30 million. Subject to reaching certain clinical development, regulatory and commercial milestones, the Group can also collect additional payments of up to US$750 million. The Group will also be entitled to collect tiered royalties on net sales within a specified period after the first commercial sale of products originating from the licensed project.
Profit attributable to shareholders of Huahong Hongli (01347) in the third quarter increased by 147.1% year-on-year, and sales revenue reached a record high
Profit attributable to parent company owners was US$123.4 million, up 147.1% year on year and 77.7% month on month. Basic earnings per share were $0.066. According to the announcement, in the past quarter, Huahong Hongli achieved sales revenue of 987.1 million US dollars, a year-on-year increase of 19.9% according to the comparable caliber after the restatement (after excluding Hualiwei, sales revenue was 803.4 million US dollars, higher than the upper limit of the range of 770 million to 780 million US dollars in the previous quarter guidelines). The gross margin was 24.6%, up 7.6 percentage points from the previous year (after excluding Hualiwei, the gross margin was 19.9%, higher than the upper limit of the 16% to 18% range of the previous quarter).
Gushengtang (02273): Plans to acquire controlling interests in Nanjing Shi Jinmo, Nanjing Baihui, Gulou Yirun and Chengdu Qingyang to expand the network of offline medical institutions
After the completion of these acquisitions, Nanjing Shi Jinmo, Nanjing Baihui, Gulou Yirun, and Chengdu Qingyang (collectively referred to as “target companies”) will become subsidiaries of the Company, so their financial results will be incorporated into the Group's comprehensive financial statements.
IMAX CHINA (01970): Net profit attributable to IMAX Corporation's shareholders in the first three quarters of US$133 million increased 289.71% year-on-year
IMAX CHINA (01970) announced the results of the controlling shareholder IMAX Corporation for the nine months ended September 30, 2026. The group obtained revenue of US$359 million, an increase of 25.88% year on year; net profit attributable to common shareholders of US$133 million, an increase of 289.71% year on year; and net profit per share of US$2.44.
FIT HON TENG (06088) net profit from continuing operations of $88,231,000 in the first three quarters decreased 15.46% year over year
FIT HON TENG (06088) announced that for the nine months ended September 30, 2026, the group achieved revenue and other operating income of US$3.883 billion, up 6.72% year on year; net profit from continuing operations was US$88.231 million, a decrease of 15.46% year on year.
Wynn Resorts, Limited, the controlling shareholder of Wynn Resorts, Limited's third-quarter operating revenue of US$108 million decreased by 39.15% year-on-year
According to the Zhitong Finance App, Wynn Macau (01128) announced the controlling shareholder Wynn Resorts, Limited's results for the third quarter of 2026. The operating revenue of the Macau business was approximately US$108 million, a decrease of 39.15% over the previous year. The adjusted property EBITDAR was approximately US$255 million, a year-on-year decrease of 17.19%.
[Individual stock prices are clear]
BeiGene (06160)'s adjusted net profit for the first three quarters was approximately US$1,358 million, up 96% year-on-year increase in annual results guidance
BeiGene (06160) announced results for the third quarter of 2026, with total revenue of about US$1.89 billion, up 34% year on year; net product revenue was approximately US$1,855 million, up 33% year on year. Net profit was approximately US$385 million, up 208% year on year; adjusted net profit was approximately US$539 million, up 77% year on year. Free cash flow was $474 million, an increase of $119 million over the same period last year.
In the first three quarters of 2026, total revenue was approximately US$5.108 billion, up 33% year on year; net profit of US$849 million, up 285% year on year; adjusted net profit was approximately US$1,358 million, up 96% year on year. GAAP gross profit margin (gross profit as a percentage of global product revenue) was 88% in the third quarter of 2026, compared to 86% in the same period last year.
The year-on-year increase in gross margin was mainly due to the increase in the share of Baiyue Ze® global sales revenue in the company's product portfolio. At the same time, benefiting from increased production efficiency, the production costs of Baiyue Ze® and Baizean® decreased, but this positive impact was offset by the loss of $22 million in non-cash intangible asset impairment associated with the company's decision to stop promoting Prybeche®. After adjustments (excluding depreciation and amortization, and excluding impairment losses described above), gross margin on product sales increased to 90% from 86% in the same period last year.